Payment overview · 2025
General Payments
$466.08
22 reported records · 13 companies
Healthcare provider profile · identity verified
Ramiro Villena, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TYLER, TX · NPI 1184690968
Verified facts
What the public records show
CMS Open Payments records show Ramiro Villena, MD received $466.08 in general payments during 2025 across 22 reported records.
Corcept Therapeutics accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $110.44 | 23.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $97.50 | 20.9% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.10 | 20.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.60 | 6.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.20 | 4.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.52 | 3.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.67 | 3.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.70 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.67 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.47 | 3.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.29 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.01 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.91 | 1.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $466.08 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $110.44 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $97.50 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $94.10 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.91 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 413 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 63 |
| Lisinopril | Lisinopril | 237 | 55 |
| Losartan Potassium | Losartan Potassium | 227 | 49 |
| Simvastatin | Simvastatin | 222 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 48 |
| Meloxicam | Meloxicam | 166 | 38 |
| Metformin Hcl | Metformin Hcl | 161 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 67 |
| Alprazolam | Alprazolam | 135 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 21 |
| Furosemide | Furosemide | 135 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 37 |
| Omeprazole | Omeprazole | 121 | 31 |
| Temazepam | Temazepam | 121 | 20 |
| Gabapentin | Gabapentin | 118 | 31 |
| Montelukast Sodium | Montelukast Sodium | 118 | 40 |
| Potassium Chloride | Potassium Chloride | 107 | 30 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 107 | 44 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 106 | 17 |
| Ezetimibe | Ezetimibe | 90 | 24 |
| Allopurinol | Allopurinol | 85 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 22 |
| Jardiance | Empagliflozin | 74 | 15 |
| Carvedilol | Carvedilol | 71 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | suppressed |
| Methylprednisolone | Methylprednisolone | 60 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 12 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Ozempic | Semaglutide | 52 | suppressed |
| Telmisartan | Telmisartan | 52 | suppressed |
| Azithromycin | Azithromycin | 51 | 50 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 11 |
| Sertraline Hcl | Sertraline Hcl | 50 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 49 | 12 |
| Glimepiride | Glimepiride | 48 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 11 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 11 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 26 |
| Eliquis | Apixaban | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 36 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Prednisone | Prednisone | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Cimetidine | Cimetidine | 35 | 15 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 16 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | 13 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 16 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $466.08 · 22 records | Corcept Therapeutics | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Kerendia, Korlym, LEQVIO, NUZYRA, QULIPTA, Symbravo, TEPEZZA, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error